1.云南省昆虫生物医药研发重点实验室,云南 大理 671000;2.大理大学 公共卫生学院,云南 大理 671000; 3.大理大学 农学与生物科学学院,云南 大理 671000;4.湘潭医卫职业技术学院,湖南 湘潭 411104
R-33
1.Yunnan Provincial Kay Laboratory of Entomological Biopharmaceutical R&D, Dali 671000, China. 2. College of Public Health, Dali University, Dali 671000. 3. Department of Agriculture and Biological Science, Dali University, Dali 671000. 4. Xiangtan Medicine and Health Vocational College, Xiangtan 411104
酒精性肝病是一种慢性进行性疾病,目前尚缺乏有效的药物治疗方法。 中药多靶点、多途径治疗疾病的特点与肠道菌群的整体调节作用高度吻合,可通过改善肠道菌群结构、恢复肠屏障功能、缓解肠道炎症反应等作用机制治疗酒精性肝病。 本文综合近年来中药调控酒精性肝病的研究进展,从肠道菌群与酒精性肝病的关系, 以及中药通过调节肠道菌群、改善肠道菌群结构、恢复肠屏障功能、缓解肠道炎症反应来发挥干预酒精性肝病的作用,以期为中药干预酒精性肝病的机制研究提供参考。
Alcoholic liver disease (ALD) is a chronic progressive disease with no effective drug therapy. The characteristics of multi-target and multi-pathway treatment using traditional Chinese medicine (TCM) are highly consistent with the overall regulation effect of the gut microbiota. TCM can be used to treat ALD by improving the gut microbiota structure, restoring the gut barrier function, and relieving gut inflammation. This report focuses on the progress in research of the use of TCM to regulate ALD, summarizes the relationship between the gut microbiota and ALD, and discusses the role of TCM in ALD in terms of its regulation of the gut microbiota, improvement of the gut microbiota structure, restoration of the gut barrier function, and relief of gut inflammation. The overall aim of this report is to provide a reference for the study of the mechanism of TCM in the treatment of ALD.
厉 颖,李灿委,范孟然,王雪雪,陶柱萍,刘卫红,尹爱武,高鹏飞.中药调控肠道菌群干预酒精性肝病的研究进展[J].中国比较医学杂志,2021,31(6):107~115.
复制